IC
CYTO

Ikarian Capital’s Altamira Therapeutics Ltd CYTO Stock Holding History

Ikarian Capital’s Portfolio CYTO Stock Details CYTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-188
Closed -$36K – 173
2022
Q2 		$36K Sell
188
-612
-77% -$198K 0.01% 136
2022
Q1 		$351K Buy
800
+38
+5% +$18.4K 0.05% 150
2021
Q4 		$553K Sell
762
-236
-24% -$158K 0.08% 124
2021
Q3 		$803K Sell
998
-13
-1% -$14.6K 0.06% 165
2021
Q2 		$1.45M Sell
1,011
-143
-12% -$196K 0.12% 148
2021
Q1 		$1.6M Buy
+1,154
New +$1.55M 0.05% 215

Other funds holding CYTO

VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ikarian Capital's CYTO Position: Q3 2022 in Review

Ikarian Capital sold out of Altamira Therapeutics Ltd (CYTO) in Q3 2022, closing a stake of 188 shares — an estimated $36K sold.

Ikarian Capital first reported a position in CYTO in Q1 2021 and held it in 6 quarters. The position peaked at $1.6M in Q1 2021. 13 funds tracked by Wall St. Rank hold CYTO as of Q3 2022.

  • Ikarian Capital reported no remaining Altamira Therapeutics Ltd position as of Q3 2022 after selling out during the quarter.
  • Ikarian Capital sold 188 Altamira Therapeutics Ltd shares in Q3 2022, an estimated $36K.
  • Ikarian Capital first reported a position in Altamira Therapeutics Ltd in Q1 2021 and held it in 6 quarters.
  • Ikarian Capital's Altamira Therapeutics Ltd position peaked at $1.6M in Q1 2021.
  • 13 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q3 2022.

Based on Ikarian Capital's 13F filing for Q3 2022, filed 14 Nov 2022.